Table 3.
Comparisons of different treatments for EGFR exon 18 mutations from various studies.
| Study | N | EGFR exon 18 subtype | Treatment | ORR | PFS |
|---|---|---|---|---|---|
| This study | 82 | G719X | A | 52.4% | 11.3 (5.6–17.0) |
| E709X | G/E/I + CT | 46.7% | 11.1 (5.9–16.4) | ||
| DelE709_T710ins D | G/E/I | 26.1% | 7.7 (4.3–11.1) | ||
| Complex G724S | CT | 39.1% | 6.2 (1.8–10.6) | ||
| Passaro et al. (19) | 42 | Single 18 mutation | G/E/A | 31.0% | 8.3 (4.9–11.7) |
| Zhang et al. (13) | 22 | Single G719X | G/E/I | 22.7% | 7.6 (4.9–10.4) |
| Complex G719 mutations | |||||
| Chui et al. (14) | 78 | Single G719X mutation | G/E | 36.8% | 6.3 |
| 9 | G719X + L861Q | 88.9% | NR | ||
| 10 | G719X + S768I | 50.0% | NR | ||
| Yang et al. (7) | 8 | SingleG719X | A | 77.8% | 13.8 (6.8–NE) |
| 10 | Complex G719 mutation | ||||
| Cho et al. (18) | 19 | G719X | O | 53.0% | 8.2 |
A, afatinib; G, gefitinib; E, erlotinib; I, icotinib; O, osimertinib; CT, chemotherapy; NR, not reached.